Sugi Predict

Sugi Predict / Compounds / SCHEMBL969120

SCHEMBL969120

SCHEMBL969120

CC(C)COc1ccc(CN)cc1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 8/20 0.52
▸ KEAP1 Q14145 1/20 0.52
▸ NFE2L2 Q16236 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ MAPT P10636 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ ST14 Q9Y5Y6 1/20 0.47
▸ POLB P06746 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ XBP1 P17861 1/20 0.45
▸ ACACB O00763 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20393931 0.98 MAOB (0.55) MAOBKEAP1NFE2L2LMNAMAPT
Acetic Acid SCHEMBL3075493 0.89 ACACB (0.51) MAOBMAPTMEN1ALOX12KMT2A
SCHEMBL21652400 0.85 MAOB (0.46) MAOBKEAP1NFE2L2LMNAST14
SCHEMBL123415 0.84 MAPT (0.55) LMNAMAPTMEN1ALOX12KMT2A
SCHEMBL11157593 0.84 TAAR1 (0.57) MAOBLMNAACACB
SCHEMBL15114294 0.83 LMNA (0.57) LMNAMAPTMEN1ALOX12KMT2A
SCHEMBL20404399 0.82 FFAR1 (0.48) MAOBKEAP1NFE2L2ST14
SCHEMBL31538932 0.81 MAOB (0.49) MAOBMAPTMEN1ALOX12KMT2A
SCHEMBL20825574 0.81 MAOB (0.49) MAOBMAPTMEN1ALOX12KMT2A
SCHEMBL13155583 0.81 ACACB (0.53) LMNAMAPTMEN1ALOX12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874103-B Continuous synthesis method of pimavanserin intermediate 4-isobutoxy benzylamine 合肥立方制药股份有限公司 2024-09-06 — — CN claimed
CN-118515606-A Tartaric acid pima method for synthesizing tryptamine 江苏宇锐医药科技有限公司 2024-08-20 — — CN claimed
CN-111303013-B Preparation method of pimavanserin 福建省微生物研究所 2023-10-13 — — CN claimed
CN-114874103-A Continuous synthesis method of pimavanserin intermediate 4-isobutoxy benzylamine 合肥立方制药股份有限公司 2022-08-09 — — CN claimed
CN-110156664-B Method for synthesizing pimavanserin 常州大学 2022-03-01 — — CN claimed
EP-3725774-B1 PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL AGENT ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) 2022-02-23 — — EP claimed
CN-106588753-B Pimanerin preparation method 重庆医药工业研究院有限责任公司 2021-07-09 — — CN claimed
EP-3828170-A1 METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE Livzon New North River Pharmaceutical Co., Ltd. (CN) 2021-06-02 — — EP claimed
CN-106518751-B Method for preparing pimavanserin 江苏先声药业有限公司 2021-05-04 — — CN claimed
US-10981871-B2 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C ACADIA PHARMACEUTICALS INC. (US) 2021-04-20 — — US claimed
EP-3351532-A1 METHOD FOR PREPARING PIMAVANSERIN SCI Pharmatech, Inc. (TW) 2018-07-25 — — EP claimed
CN-106008323-A Preparation method of pimavanserin hemitartrate crystal form C 成都百裕制药股份有限公司 2016-10-12 — — CN claimed
CN-105859608-A Method for preparing pimavanserin hemitartrate crystal form B 成都百裕制药股份有限公司 2016-08-17 — — CN claimed
CN-105481757-A Preparation method of pimavanserin BEIJING KANG LISHENG PHARMACEUTICAL TECH DEV CO LTD 2016-04-13 — — CN claimed
CN-104961672-A Synthetic method of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidine-4-yl)-N'-(4-isobutoxybenzyl)urea UNIV SHENYANG PHARMACEUTICAL 2015-10-07 — — CN claimed
EP-2289879-B1 Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt ACADIA PHARM INC (US) 2014-11-12 — — EP claimed
US-7790899-B2 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms ACADIA PHARMACEUTICALS, INC. (US) 2010-09-07 — — US claimed
EP-2146960-A2 SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS Acadia Pharmaceuticals Inc. (US) 2010-01-27 — — EP claimed
WO-2008144326-A2 SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS ACADIA PHARMACEUTICALS INC. (US) 2008-11-27 — — WO claimed
US-20070260064-A1 SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS ACADIA PHARMACEUTICALS INC. 2007-11-08 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070260064-A1 SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS MTAP, CPN1, DNPEP MAOB 2328/4885KEAP1 4879/4885NFE2L2 4521/4885
US-10981871-B2 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C NR3C2, CYP4A22, NR2C2 MAOB 757/4885KEAP1 4753/4885NFE2L2 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.